Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.

Learn More

From Promise to Therapy

Seattle Genetics is conducting clinical trials in these and other therapeutic areas:

  • Hodgkin lymphoma
  • Acute myeloid leukemia
  • Urothelial cancer
  • Breast cancer

View all clinical trials

Join The Seattle Genetics Team

We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.

Learn More

Recent News

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma More

Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma More

Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia More

View All News

Seattle Genetics At A Glance

Year founded 1998

Global Headquarters Bothell, WA

Nasdaq SGEN

Number of Employees 1,000+

Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+